Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Healthtech wearable glucose tracker Ultrahuman raises $17.5m in series B funding

Ultrahuman

Ultrahuman, the rapidly growing metabolic fitness platform, today announced it has raised $17.5 million, as it aims to help over a billion people in the world suffering from a metabolic health disorder. This brings the total funds raised so far to $25mn. Ultrahuman is committed to making metabolic fitness accessible to millions of people globally. The funds raised will be used for geographical expansion and to improve their biomarker technology. The series B funding came from Alpha Wave Incubation (AWI), which is backed by DisruptAD and managed by Falcon Edge, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund. Marquee founders and angel investors also participated including Tiger Global’s Scott Schleifer, Sandeep Singhal, Kunal Shah, Sujeet Kumar, Deepinder Goyal, Gunjan Patidar, Gaurav Munjal, Revant Bhate, Mohit Gupta, Vikram Dhingra and Roman Saini. The Ultrahuman Cyborg wearable helps people optimize their exercise and nutrition based on glucose biomarkers. The Ultrahuman wearable launched in June 2021 has already amassed thousands of users in the waitlist with users raving about their experience on Twitter after using the wearable. The metabolic health crisis is unarguably one of the largest healthcare crises that exists today. Over a billion people in the world suffer from a metabolic health disorder which contribute to almost 85% of all chronic diseases in the world. By helping people understand how food and exercise affects their metabolic health, people would be able to make informed choices about what they eat and their activity levels. The approach is a geography / diet agnostic way to help people eat and exercise better. A single biomarker like glucose can reveal so much about how a particular food item affects the user’s metabolic health by measuring the glucose response. This response is unique to an individual and it depends on various factors like their microbiome diversity, stress levels, time of the day, food ingredient quality etc. Ultrahuman was started by Mohit Kumar and Vatsal Singhal who were also co-founders at Runnr that later merged with Zomato. Mohit is an avid cyclist, biohacker and Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross fit enthusiast and biohacker. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai). There he observed athletes train smartly via usage of data, recovery tools and protocols. He got together with Vatsal and they came up with a vision for Ultrahuman where they can make the journey of fitness for people more personalised and impactful. “Biomarkers will change how the fitness and the healthcare industry works. By being able to continuously monitor their biomarkers like glucose, users can not only avoid chronic diseases but make lifestyle changes that help them improve their fitness levels for longevity and performance, ” said Ultrahuman Founder and CEO Mohit Kumar. Navroz D. Udwadia, Co-Founder, Falcon Edge Capital, said, " We are excited to partner with Mohit and Vatsal, founders of Ultrahuman. We believe they can transform the way people view personal wellness globally. Their thoughtfulness around UI / design and consumer experience is inspiring. We are thrilled to back what could be a pioneering biomarker-driven global healthcare business. Their dual obsessiveness around product engineering and customer experience is already showing result in terms of product market fit and retention. ” Commenting on the investment, Ravi Mehta, Founder and MD Steadview Capital, said, “ We are excited to be a part of Ultrahuman’s journey as it takes what we believe to be a disruptive approach to personal wellness. Ultrahuman’s biosensor-enabled, data-first model, in our view, is the future of any personalized healthcare ecosystem, ” “We at Nexus are super excited about Ultrahuman’s biomarker based approach to build hyper- personalised diet and exercise journeys for users. We are seeing a very strong pull for Ultrahuman’s Cyborg platform globally and feel that it will be a foundational approach to personal wellness in the years to come, ” added Sameer Brij Verma, MD Nexus Venture Partners. “Mohit and team have taken their personal fitness journeys and translated them to a world class product and experience in just over a year. We expect Ultrahuman to help shape how health is proactively monitored across global audiences, “ said Karthik Reddy, Founder of Blume Ventures. About Ultrahuman Ultrahuman is headquartered in the US and India. It is the world's most advanced metabolic fitness platform. It helps people create long-term habits and changes via instant nudges and deep health insights instead of diets and strict exercise routines. For more information and updates on Ultrahuman, please visit ultrahuman.com Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com

August 19, 2021 08:00 AM Pacific Daylight Time

Image

Cloud Conventions Introduces SafetyNet to Create a Virtual Backup Plan for Live Events

Convey Services

Cloud Conventions today introduced SafetyNet ™, a new program to provide a virtual event backup options for associations, tradeshows, event managers or trade groups that have a live event scheduled now or in the near future. SafetyNet provides a standby virtual event platform that can be activated if needed when attendance for a live event declines or if there is a requirement to pivot to an all-virtual program. A SafetyNet platform can be brought online in a matter of days without technical support or programming. Cloud Conventions is a sophisticated event management platform that redefines the attendee and exhibitor experience with a strong focus on delivering virtual and hybrid events, regardless of size or budget. “It seems like a repeat of 2020 as event managers, associations and other trade groups are struggling to decide if they should cancel their live event, shift to virtual or hybrid, or take other precautions to make attendees and exhibitors feel safe,” said Carolyn Bradfield, CEO of Cloud Conventions. “Any group hosting live events today needs a virtual backup plan that can be activated to ensure attendees and sponsors can participate in industry sessions, continuing education and still make connections that they would miss when they can’t attend in person.” SafetyNet maintains a low-cost Cloud Conventions virtual platform on standby behind a private login until required. It is hosted on a custom URL, is fully branded, customized and organized to host live or on-demand sessions, exhibitor and sponsor booths or provide a resource center for all event-related content. Attendees can be imported from a live event registration system and have their record transferred to SafetyNet including demographics and event access permissions. Sponsors are assigned a virtual booth template and configured to go live without technical assistance, in a matter of hours. “Now that live events have partially returned, many groups ask themselves if virtual events are worth it, so they only focus on their in-person event, often to their detriment,” added Bradfield. “A 2020 study of 1,000 respondents, ‘ Association Trends: From Disruption to Opportunity’ produced by Community Brands, details that having a virtual option for membership participation has changed from a nice-to-have to a must have. Some live events scheduled for the fall of 2021 are being abruptly cancelled due to on-going COVID risks. This is clearly an indicator that the pandemic is far from over. A SafetyNet option is the best insurance that the show will go on, no matter what.” SafetyNet is offered for a low, setup fee to create a fully branded and configured virtual environment. If the organizer chooses to go live with a hybrid or all-virtual event, the setup fee applies to the event package. Show managers can choose as much or as little assistance from Cloud Conventions to bring their event online quickly with all the features needed to educate and engage attendees. Having a virtual option guarantees a rewarding experience for attendees, better ROI for sponsors and ensures smoother event operation for organizers. Explore SafetyNet at: https://cloudconventions.com/page/139455/safetynet. About Cloud Conventions Cloud Conventions from Convey Services is Cloud Conventions is an enterprise virtual/hybrid event management platform that redefines the exhibitor and attendee experience to allow companies to provide easy access to in-depth product information, showcase their brands with graphics and videos, create calls to action and generate immediate sales leads. Used around the world for large managed events and smaller self-directed meetings, conferences and corporate kickoffs, Cloud Conventions automates exhibitors and virtual booths, continuing education, speaker sessions and reminders, invitations and email communication, while at the same time producing detailed analytics on attendee, session and exhibitor activity. Cloud Conventions supports multiple languages and currencies, internal, external and single-sign on registration, and supports all conferencing carriers and platforms. Trade Associations and event managers can explore all of the Cloud Conventions solutions by visiting https://cloudconventions.com or contacting info@cloudconventions.com or call 888-975-1382. Cloud Conventions™, Community™, SafetyNet™, Cloud Kickoffs™, Conduct™, One-Touch Email Share™, Hub & Spoke™, 360° Virtual Exhibit Hall & Lobby Experience™ and ListLock™ are trademarks of Convey Services LLC Contact Details Bruce Ahern +1 770-580-0810 bahern@conveyservices.com Company Website https://cloudconventions.com

August 19, 2021 10:29 AM Eastern Daylight Time

American Kidney Fund Commends the CDC, FDA and CMS for Supporting a Booster Shot of the COVID-19 Vaccine for Immunocompromised People

American Kidney Fund

LaVarne A. Burton, President and CEO of the American Kidney Fund (AKF), today issues the following statement in response to guidance from the Centers for Disease Control (CDC) and authorization from the Food and Drug Administration (FDA) allowing immunocompromised people to receive a COVID-19 vaccine booster shot: “People who are immunocompromised, including kidney transplant recipients, have been living with fear and uncertainty ever since research showed that they were less likely to develop antibodies from COVID-19 vaccines. AKF and the patients we serve are grateful to CDC and FDA for moving quickly to support a booster shot recommendation for those who had the Pfizer-BioNTech or Moderna vaccines and are solid organ transplant recipients or are diagnosed with conditions that are considered to have a similar level of immunocompromise. This extra layer of protection against COVID-19 comes as much-needed reassurance for patients who have a significantly higher risk of severe illness, hospitalizations and death from the coronavirus. “Further, AKF is grateful that the Centers for Medicare and Medicaid Services has announced that Medicare will cover the cost of this booster shot for Medicare beneficiaries. “Anyone who is uncertain about whether they qualify for this booster shot should speak with their physician. “AKF urges the CDC and FDA to quickly assess whether those who received the Johnson & Johnson vaccine should also receive a booster shot. “While getting the vaccine, and a booster shot, are strongly encouraged for those who are immunocompromised, it is still important for the kidney community to take CDC-recommended precautions, like wearing masks in public places and practicing social distancing, to protect themselves from COVID-19, particularly as cases from the Delta variant surge across the U.S. “If people who are immunocompromised become exposed to COVID-19, it is critical to speak with their doctor or care team and seek treatment with antibody therapy right away. The FDA’s recent emergency use authorization of a preventive monoclonal antibody treatment for those who are immunocompromised is a great step towards preventing serious illness in this patient population. However, this treatment is primarily available at large hospitals and health systems in large urban areas, meaning that patients in rural areas or those without adequate transportation may not have access to this beneficial treatment. Additionally, education about the possibly of getting post-exposure antibody treatment is critical, and factors like internet access and health literacy put some at a disadvantage. “Ensuring equitable dissemination of the vaccine, the booster shot and antibody treatment to protect immunocompromised individuals continues to be a challenge that needs to be prioritized. As new information and research becomes available, AKF will continue keeping kidney patients informed and advocating for the protections they need in their fight against kidney disease.” For more information about COVID-19 and kidney disease, visit KidneyFund.org/covid-19. Kidney patients can access additional COVID-19 resources at KidneyFund.org/coronavirus. ### About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Stefanie Tuck 11921 Rockville Pike, Suite 300, Rockville, MD 20852 +1 202-470-1797 AKF@jpa.com Company Website http://www.kidneyfund.org/

August 18, 2021 09:00 AM Eastern Daylight Time

Cyvatar’s Stephanie Simpson Named a Finalist for the Top 10 Women in Cybersecurity at the 2021 Black Unicorn Awards

Cyvatar

Cyvatar today announced the selection of another member of its senior executive team as a finalist for outstanding achievement at this year’s Cyber Defense Magazine Black Unicorn awards, announced during the 2021 Black Hat USA conference. Stephanie Simpson, vice president of platform management, was chosen as a finalist for the Top 10 Women in Cybersecurity; she competed against the industry’s leading cybersecurity experts for this prestigious award. “We’re pleased to name Stephanie Simpson as a finalist for the Top 10 Women in Cybersecurity among an elite group of female information security professionals at the third annual Black Unicorn awards,” said judges Robert R. Ackerman Jr., David DeWalt, Dr. Peter Stephenson, and Gary Miliefsky. “This year’s competition was fierce, and she should be proud of her achievement.” Stephanie was selected from women around the world who vied for top honors. She has two decades of software product leadership, from ideation to launch, to fill gaps in the industry and meet customer needs. She has brought many award-winning innovations to market including Cyvatar’s cybersecurity-as-a-service (CSaaS) platform, developed with fellow Black Unicorn winner Craig Goodwin. As an engineer, Stephanie is no stranger to disruptive technologies, and customers and colleagues alike benefit from her passionate, transformative leadership style. “Female technical talent in cybersecurity is hard to find, and we’re fortunate to have such an accomplished practitioner as Stephanie on the executive team at Cyvatar,” said Corey White, Cyvatar co-founder and chief executive. “Diversity and inclusion are foundational to our success, which makes Stephanie’s vision, energy, and leadership vital as we recruit top talent across the organization.” Only Cyvatar offers subscription-based CSaaS designed to provide outcomes, continuous remediation, ongoing solution maintenance, and the ability for all of its customers to execute their security strategies at speed and scale. Find out how CSaaS can work for your business at cyvatar.ai. About Cyber Defense Awards This is Cyber Defense Magazine’s 9th year of honoring cybersecurity innovators, in this case the Black Unicorn Awards for 2021 on our Cyber Defense Awards platform. In this competition, judges for these prestigious awards includes cybersecurity industry veterans, trailblazers and market makers Gary Miliefsky of CDMG, Dr. Peter Stephenson of CDMG, Robert R. Ackerman Jr. of Allegis Cyber and David DeWalt of NightDragon with much appreciation to emeritus judge Robert Herjavec of Herjavec Group. To see the complete list of finalists for the Black Unicorn Awards for 2021 please visit https://cyberdefenseawards.com/black-unicorn-awards-finalists-2021/ About Cyvatar Cyvatar is committed to making cybersecurity effortless for everyone. As the industry’s first subscription-based, cybersecurity-as-a-service (CSaaS) company, it’s our mission to transform the way the security industry builds, sells, and supports cyber solutions. We empower our members to achieve successful outcomes by providing expert advisors, proven technologies, and a strategic process roadmap to guarantee results that map to their business drivers. Our approach is rooted in proprietary ICARM (installation, configuration, assessment, remediation, maintenance) methodology that delivers smarter, measurable security solutions for superior compliance and cyber-attack protection faster and more efficiently, all at a fixed monthly price. And because we’re a subscription, members can cancel anytime. Cyvatar is headquartered in Irvine, California with locations around the world. Begin your journey to security confidence at https://cyvatar.ai/ and follow us on LinkedIn and Twitter. Contact Details Cyvatar KC Higgins +1 303-434-8163 kc@cyvatar.ai Company Website https://cyvatar.ai/

August 16, 2021 12:00 PM Eastern Daylight Time

Elsevier launches advanced clinical tool to bring world-class medical content to physicians globally at the point of care

Elsevier

Elsevier, a global leader in research publishing and information analytics, is pleased to announce the launch of an enhanced version of ClinicalKey ®, which will provide physicians with quick access to Elsevier’s trusted medical resources in addition to clinical decision support at the point of care. The new ClinicalKey for physicians in the U.S. and various international markets will help them diagnose and treat patients faster, and more effectively, based on the latest evidence. This enhancement is coming as time-pressed clinicians are facing the daunting task of having to keep current with a high volume of medical research output. The rate at which medical knowledge has been expanding in recent history is exponential. In 1950, the total amount of medical research doubled in approximately 50 years. This accelerated to 7 years in 1980; 3.5 years in 2010; and just 73 days in 2020 1. Recognizing this issue, Elsevier conducted extensive research with hundreds of clinicians and leveraged global insights to inform the development of a solution that would support them with patient care in an environment where evidence-based data and guidance changes quickly. Elsevier also partnered with institutional leaders to evolve ClinicalKey and help address these challenges. Dr. Romil Chadha, MD, MPH, FHM, FACP, Assistant Chief of Operations, Division of Hospital Medicine, UK Health Care, who collaborated with Elsevier to help develop the next version of ClinicalKey, said: “As a practicing physician, and leader of a team of hospital clinicians, I have seen first-hand the realities of information overload for healthcare professionals and the challenges it presents. There is a strong need in the healthcare industry for a single solution that enables clinicians to make fast decisions at the point of care with confidence, because they are based on the latest evidence. I was honored to work with Elsevier to redesign ClinicalKey to help meet this need.” 2 While ClinicalKey will retain all current elements and functionality as a reference resource, it now includes new features that make it easier to use for clinical decision support, such as: New user interface: The cleaner interface leverages existing clinical workflows to naturally align with each user’s thought process to improve content discovery. Represented by a system of colors and icons, each page includes a clear visual hierarchy of factors such as importance, relevance, and recurrence, to help clinicians in their process of finding an answer to their question. Improved search functionality: The new search interface supports clinicians by getting them the information they need in the moment they need it. A powerful algorithm instantly provides the most relevant and comprehensive content, while also allowing the ability to quickly drill down to precise pieces of information. Significant Point of Care content: Clinicians have quick access to both in-depth research materials and concise, summarized content. The dynamic linkage between the content types promotes an easy and fast experience when diagnosing a patient or creating a treatment plan, without having to repeat a search query. The ability to access high-level content that is based on volumes of evidence-based research, is helping clinicians save precious time in emergency situations that require quick and confident decisions for patient care. Jan Herzhoff, President, Health, Elsevier said: “The responsibilities of clinicians today are becoming increasingly complex with more and more patients presenting with comorbid, chronic conditions that can be difficult to manage, especially in today’s fast-paced, demanding healthcare environment. This next generation of ClinicalKey is deeply rooted in learnings that we made with our partners from across the globe, combined with the latest design thinking. It supports every moment in the healthcare continuum with trusted, evidence-based answers, from quick point-of-care answers to deep clinical research through one single search.” Elsevier has been working continuously to enhance its global portfolio of clinical solutions, making these tools more responsive and accessible at the point of care. During the process of building and enhancing ClinicalKey, local solutions in specific international regions have also been developed. These include ClinicalKey China, and ClinicalKey Now, a solution that responds to needs in key local markets outside of the U.S., so that they can have confidence in their decisions to sustain continuity of care for patients. Other products in Elsevier’s portfolio include ClinicalPath, an evidence-based oncology pathways embedded in the clinical workflow to allow oncology practices to predict, measure and manage treatment decisions and costs, and Elsevier Clinical Nursing which combines trusted evidence and technology to empower nurses to excel. To learn more about ClinicalKey and the unique experience it provides users, please visit its website. --- Note for editors 1 Densen P. “Challenges and opportunities facing medical education”. Trans Am Clin Climatol Assoc. 2011;122:48-58. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116346/ 2 Dr. Romil Chadha’s quote represents the opinions of the author and not that of the University of Kentucky or UK HealthCare. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Elsevier Teresa Mueller, Vice President, Global Health Markets +31 6 20987384 t.mueller@elsevier.com Company Website https://www.elsevier.com/

August 16, 2021 08:00 AM Eastern Daylight Time

Image

Cyvatar’s Craig Goodwin Named a Finalist for the Top 10 Cybersecurity Experts at the 2021 Black Unicorn Awards

Cyvatar

Cyvatar today announced the selection of a member of its senior executive team as a finalist for outstanding achievement at this year’s Cyber Defense Magazine Black Unicorn awards, announced during the 2021 Black Hat USA conference. Craig Goodwin, Cyvatar co-founder and chief product and strategy officer, was selected as a finalist for the Top 10 Cybersecurity Experts; he competed against the industry’s leading cybersecurity experts for this prestigious award. “We’re pleased to name Craig Goodwin as a finalist for the Top 10 Cybersecurity Experts among the elite group of information security professionals at the third annual Black Unicorn awards,” said judges Robert R. Ackerman Jr., David DeWalt, Dr. Peter Stephenson, and Gary Miliefsky. “This year’s competition was fierce, and he should be proud of his achievement.” Craig was selected from security practitioners around the world that vied for top honors. He is a battle-tested CISO who has built a successful career delivering transformative IT and security programs by combining holistic security, IT, and business leadership expertise to produce extraordinary results. Craig’s innovation brings the membership economy to cybersecurity with Cyvatar’s CSaaS platform, which is rapidly becoming the de facto operating system for today’s security programs. “At a time when so many companies struggle to find top security resources, we’re blessed to have an exceptional talent like Craig leading company strategy,” said Corey White, Cyvatar co-founder and chief executive. “Because we offer cybersecurity as a service, people are the lifeblood of our organization. The work Craig and his team have done to bring the award-winning Cyvatar platform to customers enables us to deliver fast, affordable, fully managed security programs to any size business at prices that don’t break the bank. His achievement means no customer has to go without the very best cybersecurity available today.” Only Cyvatar offers subscription-based CSaaS designed to provide outcomes, continuous remediation, ongoing solution maintenance, and the ability for all of its customers to execute their security strategies at speed and scale. Find out how CSaaS can work for your business at cyvatar.ai. About Cyber Defense Awards This is Cyber Defense Magazine’s 9th year of honoring cybersecurity innovators, in this case the Black Unicorn Awards for 2021 on our Cyber Defense Awards platform. In this competition, judges for these prestigious awards includes cybersecurity industry veterans, trailblazers and market makers Gary Miliefsky of CDMG, Dr. Peter Stephenson of CDMG, Robert R. Ackerman Jr. of Allegis Cyber and David DeWalt of NightDragon with much appreciation to emeritus judge Robert Herjavec of Herjavec Group. To see the complete list of finalists for the Black Unicorn Awards for 2021 please visit https://cyberdefenseawards.com/black-unicorn-awards-finalists-2021/ About Cyvatar Cyvatar is committed to making cybersecurity effortless for everyone. As the industry’s first subscription-based, cybersecurity-as-a-service (CSaaS) company, it’s our mission to transform the way the security industry builds, sells, and supports cyber solutions. We empower our members to achieve successful outcomes by providing expert advisors, proven technologies, and a strategic process roadmap to guarantee results that map to their business drivers. Our approach is rooted in proprietary ICARM (installation, configuration, assessment, remediation, maintenance) methodology that delivers smarter, measurable security solutions for superior compliance and cyber-attack protection faster and more efficiently, all at a fixed monthly price. And because we’re a subscription, members can cancel anytime. Cyvatar is headquartered in Irvine, California with locations around the world. Begin your journey to security confidence at https://cyvatar.ai/ and follow us on LinkedIn and Twitter. Contact Details Cyvatar KC Higgins +1 303-434-8163 kc@cyvatar.ai Company Website https://cyvatar.ai/

August 11, 2021 07:00 AM Eastern Daylight Time

Seasoned HR Expert Joins Phase 4 Services to Offer Advice on Developing Strong Teams and Maintaining Workplace Culture

Phase 4 Services

Phase 4 Services, a laboratory management and consulting firm focused on supporting and growing hemp and cannabis testing labs, has hired experienced HR maven Kara Mittan to lead their human resources and administrative operations team. As VP of Human Resources, Mittan will assist Phase 4’s laboratory clients with effectively scaling their teams and implementing systems designed to maintain employee satisfaction and increase productivity. “We’ve seen first hand what challenges can arise when you go from a small, tight knit team to a large organization with multiple departments,” said Michael Kahn, Founder and CEO of MCR Labs, a cannabis testing lab operating in several Northeast cannabis markets. “Without Kara guiding the process and putting the tools in place to help us grow effectively, we likely would not have had the same success we've achieved in keeping pace with how fast this industry is expanding.” Having served as an HR director at several organizations since 2008, Mittan has significant experience across a diverse array of industries including international companies coordinating operations on multiple continents. Phase 4 Services is gaining critical HR knowledge and insight with Mittan’s addition to the consulting team. This will enable the firm to better guide clients in regards to building strong teams, fostering intra-organizational communication, and developing a healthy workplace culture. About Phase 4 Services: Phase 4 Services is a scientific consulting and laboratory management firm dedicated to growing, supporting, and enhancing hemp and cannabis testing laboratories. Founded by experts in analytical testing, pharmaceutical chemistry, business administration, and development strategy, our team is equipped with the knowledge and experience necessary to ensure partner laboratories are successful in their pursuit of advancing public health and safety for cannabis patients and consumers. For more information visit http://phase4services.com. Contact Details Phase 4 Services Joe Crinkley +1 857-230-0839 PR@phase4services.com Company Website https://phase4services.com/

August 10, 2021 10:39 AM Eastern Daylight Time

ZIPPZ CBD Taps Renowned Medical Advisors, Dr June Chin, and Dr Jessica Knox

ZIPPZ

ZIPPZ, the first-of-its-kind personalized natural CBD wellness company, has announced the addition of two renowned cannabis medical advisors to the brand: Dr. June Chin and Dr. Jessica Knox, both cannabinoid and preventive medicine physicians. As cannabis becomes more widely consumed with 22.2 million users each month, the U.S. legal market is anticipated to hit $43 billion by 2025. Cue in the rapidly growing market of cannabis-based products with minimal physician involvement, and you have a nation of consumers seeking quality medicinal remedies. Disrupting the sleep and stress market, ZIPPZ provides an alternative to OTC and Rx therapies with innovative CBD and plant-based solutions. Using the natural pharmacology-based approach from their practices, Dr. Chin, and Dr. Knox will apply their knowledge to help ZIPPZ elevate cannabis as a holistic medical alternative. “ZIPPZ understands that sleep disruption and increased levels of stress and anxiousness are driven by dramatically different things for different people,” says ZIPPZ CEO, Scott Eagle.”The solution requires a unique and personalized product catered to each individual’s health needs, not a generic one-size-fits-all approach. We are thrilled to welcome Dr. Chin and Dr. Knox to help guide our custom solutions and advance our mission as an integrative medical approach.” “As a chronic pain survivor, I have been an advocate for the application of medical cannabis throughout my career”, stated Dr. Chin. “More integrative and holistic approaches to patient care is exactly what we need. I’m honored to work with the ZIPPZ team to advance this important vision while creating affordable and personalized CBD therapies for those who seek relief from stress and pain.” As part of ZIPPZ’s unique approach, the brand leverages each customer’s robust online assessment for a sophisticated understanding of their unique condition, severity, age, gender, and lifestyle. ZIPPZ then personalizes formula recommendations for each individual, offering a “trial sampling” program, in which users finalize the perfect ZIPPZ formula to meet their needs. Dr. Knox stated, “I am particularly drawn to the ZIPPZ personalized consumer assessment, as health needs should be treated for individual requirements. I look forward to applying my experience in refining the cannabinoid system and medical applications to advise ZIPPZ on their vision that each customer receives a unique remedy for their health and wellness needs.” By integrating network pharmacology principles, ZIPPZ has maximized the effectiveness of 35 proven botanicals, including CBD, to formulate products to meet each consumer’s unique needs. ZIPPZ offers hundreds of potential formula combinations, paving the way in providing credible and natural wellness therapies that work. ### ABOUT ZIPPZ: ZIPPZ is a direct-to-consumer, California-based CBD wellness company offering personalized, scientifically-formulated CBD solutions targeting sleep, stress, and anxiousness. Founded by a team of physicians, clinicians, scientists, and technologists, ZIPPZ dismisses the one-size-fits-all approach to CBD therapies. After consumers complete a quick and thorough 3-minute assessment, ZIPPZ uses data science to help match them with personalized solutions. Rooted in nature and activated by science, ZIPPZ combines CBD with 35 carefully selected botanicals to deliver therapies customized to each individual’s needs. A leader in the revolution of personalized CBD therapies, ZIPPZ offers over 250 combinations of products that provide fast and effective relief. ABOUT DR JUNE CHIN: Dr June Chin is an integrative cannabinoid medicine physician, having received her Medical Degree from Touro University and her BS- Nutrition & Food Science, Biochemistry from Cornell University. She is a Board Member of American Academy of Cannabinoid Medicine, Association for Cannabis Health Equity and Medicine (ACHEM), Co-founder & Medical Director at Medical Cannabis Mentor, Chief Medical Advisor at CannabisMD.com & Miraculo, and Chief Medical Advisor at Artemis CBD Shop. Dr Chin is also a chronic pain survivor. As a result of her experience, Dr. Chin decided to dedicate her medical career to finding effective, integrative and holistic approaches to patient care. Dr. Chin is also a frequent keynote speaker on the science and medicine of cannabis and has spoken at hospitals, conferences, and events all over the world. ABOUT DR JESSICA KNOX: Dr. Jessica Knox is a board-certified preventive medicine physician, having earned her bachelor’s degree from Harvard University before going on to earn her medical and business degrees from Tufts University. After completing her residency in preventive medicine, Dr. Knox began her study of the endocannabinoid system and cannabis medicine. She has spoken on numerous medical cannabis panels, presented at cannabis conferences nationwide, and appeared on nationally televised programs and global webcasts to discuss the burgeoning fields of Endocannabinology™ and Cannabinoid Medicine. Dr. Knox is a co-founder and CEO of the American Cannabinoid Clinics, and cofounder of Pivital Edu. She is also a co-founder and executive board member of the Association for Cannabis Health Equity and Medicine ( ACHEM ). --- To learn more, visit: zippz.com. Instagram: @zippzwellness Twitter: @zippzwellness Facebook: @zippzwellness *Statistics included from ‘CDC’, Marijuana Fast Facts and Fact Sheets and ‘Intrado Global Newswire’, Cannabis Capital Raises Triple to USD $6 Billion in First Half of 2021 Contact Details Jive PR + Digital Lynsey Gray +1 250-505-6434 lgray@jiveprdigital.com Company Website https://zippz.com/

August 10, 2021 07:00 AM Pacific Daylight Time

LivLyme Foundation Founder Olivia Goodreau to Discuss Perils of Lyme Disease in Free Webinar Hosted by Industry-Leading Quidel Corporation

Quidel Corporation

Olivia Goodreau, who founded the LivLyme Foundation at 12 years old and has since become a widely respected advocate and national spokeswoman for Lyme disease prevention and treatment, will discuss her “journey with Lyme” and the importance of early testing as part of a webinar to be held Thursday, Aug. 19. The webinar is the latest in an ongoing series sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. ______________________________________________________________________ Webinar Registration The free online educational program will take place Aug. 19 at noon EDT. Registration is available now at https://education.quidel.com/registration/2580/1/r/LD-1. You may attend the webinar by accessing the same link on or after Aug. 19 at noon EDT. ______________________________________________________________________ Now 16 years old, Goodreau founded the LivLyme Foundation in 2017 to help raise money for individuals who cannot afford their Lyme medication or doctors’ visits and to fund research to find a cure for Lyme and tick-borne diseases. She has since awarded 54 grants to children and adults ages 2-21 along with four grants to top universities to fund tick-borne disease research. Goodreau is also the inventor of TickTracker, the free global app that has over 50,000 users in multiple languages worldwide. TickTracker was selected by the U.S. Department of Health and Human Services as the “top tech tool” that is solving global health problems, beating out Oracle and IBM, among others. As part of the webinar, Goodreau will discuss her journey with Lyme, including when she became ill, the number of physicians she visited, how she was diagnosed and her passion for the importance of early testing. She will also discuss her work on the “public stage,” having presented TickTracker at the White House and having met with countless members of Congress, celebrities, scientists and governmental agencies to educate and spread awareness about tick-borne diseases. Goodreau’s webinar presentation is particularly relevant today as Lyme disease is on the rise to record numbers throughout the country and has the potential to affect as many as 476,000 citizens before the year is out. For accurate and fast testing, more and more clinicians are turning to the Sofia® 2 Lyme FIA by Quidel. This revolutionary test provides the patient and physician with indicative results within 15 minutes, as opposed to days, which has historically been the norm (and during which time organisms can spread and become systemic). It can be performed in the privacy of a doctor’s office, local clinic or even by a nurse at a children’s summer camp; and it is the only test that can get results from a simple finger prick of blood. Among those expected to attend the free Aug. 19 webinar are physicians; allied health professionals; health researchers; and representatives of physician offices, laboratories, urgent care centers, patient advocacy associations and others interested in the subject. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

August 10, 2021 09:00 AM Eastern Daylight Time

1 ... 257 258 259 260 261 ... 301